SCHEMBL3619081

SCHEMBL3619081

CCOc1cc(OC)ccc1[C@@H](CCC(=O)N(CC(C)(C)OC(=O)O)OC(C)(C)C)N1Cc2cccc(NC(=O)C3CC3)c2C1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
GAA P10253 2/20 0.37
ALOX12 P18054 1/20 0.37
NR1I2 O75469 1/20 0.34
UGCG Q16739 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALOX15 P16050 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1826997 0.89 PDE4B (0.39) NR1I2UGCGTSHRMEN1KMT2A
SCHEMBL3619080 0.87 MAPT (0.38) MAPTGAAALOX12NR1I2UGCG
SCHEMBL1380543 0.76 PDE4B (0.42) NR1I2UGCGTSHRMEN1KMT2A
SCHEMBL1826996 0.76 PDE4B (0.42) NR1I2UGCGTSHRMEN1KMT2A
SCHEMBL3561288 0.75 PDE4B (0.41) NR1I2UGCGTSHRMEN1KMT2A
SCHEMBL1826872 0.73 TNF (0.40) ALDH1A1MEN1KMT2A
SCHEMBL1828096 0.73 TNF (0.40) ALDH1A1MEN1KMT2A
SCHEMBL6843737 0.73 PDE4B (0.45) TSHRMEN1KMT2A
SCHEMBL3561283 0.72 PDE4B (0.42) NR1I2UGCGTSHRMEN1KMT2A
SCHEMBL3528755 0.71 PDE4B (0.43) NR1I2UGCGTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267800-A1 N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses CELGENE CORPORATION 2010-10-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267800-A1 N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses PDE4A, PDE12, PDE4B MAPT 3511/4885GAA 44/4885ALOX12 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.